MedTrace Logo

Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders

NCT00704106 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-11-14

No results posted yet for this study

Summary

We propose a largely retrospective study with short-term prospective follow-up in a subgroup of patients who have not yet been treated with 48 weeks of entecavir following partial response to adefovir. The aim of the study is to describe sequential virologic response to adefovir and entecavir.

Conditions

Interventions

DRUG

Entecavir

0.5 or 1 mg dose qd

Sponsors & Collaborators

Principal Investigators

  • Huy N Trinh, M.D. · Pacific Health Foundation

  • Mindie H Nguyen, M.D., M.A.S. · Pacific Health Foundation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704106 on ClinicalTrials.gov